Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul 21;106(29):12061-6.
doi: 10.1073/pnas.0905441106. Epub 2009 Jul 2.

Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus

Affiliations

Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus

Dwight H Kono et al. Proc Natl Acad Sci U S A. .

Abstract

Using the Unc93b1 3d mutation that selectively abolishes nucleic acid-binding Toll-like receptor (TLR) (TLR3, -7, -9) signaling, we show these endosomal TLRs are required for optimal production of IgG autoAbs, IgM rheumatoid factor, and other clinical parameters of disease in 2 lupus strains, B6-Fas(lpr) and BXSB. Strikingly, treatment with lipid A, an autoAb-inducing TLR4 agonist, could not overcome this requirement. The 3d mutation slightly reduced complete Freund's adjuvant (CFA)-mediated antigen presentation, but did not affect T-independent type 1 or alum-mediated T-dependent humoral responses or TLR-independent IFN production induced by cytoplasmic nucleic acids. These findings suggest that nucleic acid-sensing TLRs might act as an Achilles' heel in susceptible individuals by providing a critical pathway by which relative tolerance for nucleic acid-containing antigens is breached and systemic autoimmunity ensues. Importantly, this helps provide an explanation for the high frequency of anti-nucleic acid Abs in lupus-like systemic autoimmunity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Immunopathology of B6-Faslpr 3d mice. (A) IgM and IgG polyclonal and autoAbs from 6- to 8-month-old B6-Faslpr wild-type (wt/wt), heterozygous (wt/3d), and mutant (3d/3d) mice determined by ELISA. IgM RF was anti-IgG1, 4–22 mice/group. (B) Representative ANA results from 6- to 7-month-old mice (1/100 dilution), 4–7/group. (C) Lymphoid organ weights: spleen and LN (cervical, axillary, inguinal, and mesenteric) weights from 10-month-old mice, 5–7/group. (D) Representative flow cytometry analyses of splenic B cell subsets in young (1 month) or old (15 month) mice with the Faslpr and 3d mutations. Follicular (CD21lo CD23hi), marginal zone (CD21hi CD23lo), and CD21lo CD23lo populations are gated (see Table S3). (E) Cumulative survival, 8–11/group. P < 0.04 for 3d/3d versus wt/wt or wt/3d.
Fig. 2.
Fig. 2.
AutoAbs and survival of 3d BXSB background mice. (A) Serum IgM and IgG anti-nuclear Abs from 3- to 4-month-old mice (mean ± SE, 4–5/group). (B) Serum IgG anti-RNP from 3- to 4-month-old mice, 7–8 mice/group. (C) Cumulative survival, 10–12 mice/group, P < 0.0001.
Fig. 3.
Fig. 3.
IgM and IgG polyclonal and autoAbs from lipid A-treated B6-Faslpr wt and 3d mice. Six-week-old mice were given 50 μg lipid A i.p. 2 times per week for 20 weeks. Ig amounts are by ELISA (mean ± SE for 3–6/group at each time point). *, P < 0.05.
Fig. 4.
Fig. 4.
B and T cell responses in B6-Faslpr 3d mice. (A) TI-1 anti-TNP response. Sera were from 7 days after 50 μg TNP-LPS i.p. Total Ig and Abs to high-density (TNP-15) or low-density (TNP-3) TNP conjugates were measured by ELISA. P > 0.05 for wt vs. 3d in all groups. (B) TD anti-TNP response was measured serially in mice immunized with TNP-KLH on days 0 and 21 either in CFA for the first dose and IFA for the second (CFA/IFA) or in alum for both doses (mean ± SE from 3–11/group). P-values comparing wt and 3d groups are shown below their respective time points: Upper line for CFA/IFA and Lower line for alum-injected mice. (C) Recall of T cell proliferation of wt and 3d T cells to OVA with either wt or 3d APCs. Splenic T cells and APCs were isolated 10 days after immunization with OVA in CFA and proliferation was assessed by thymidine uptake after 4 days. One of 2 independent experiments is shown.
Fig. 5.
Fig. 5.
TLR-independent activation of DCs. (A) DC activation with cytoplasmic dsRNA and 5′ (3P)-RNA. Bone marrow (BM)-derived wt, 3d, and MyD88−/−/Trif−/− double-knockout DCs were transfected with 250 μg/mL poly(I:C) alone or by Lipofectamine with 10 μg/mL poly(dT:dA*dA:dT) or 200 ng 5′ (3P)-dsRNA. Poly(I:C) in high concentrations directly enters cells. P < 0.009 for all wt, 3d, and MyD88−/−/Trif−/− double-knockout DCs transfected with RNA versus Lipofectamine-treated (Lipo) DCs. (B) DC activation with cytoplasmic double-stranded mammalian DNA. DCs from wt, 3d, and TLR9−/− mice were transfected with 10 μg/mL calf thymus DNA. P < 0.05 for dsDNA-transfected wt, 3d, and TLR9−/− DCs versus Lipo alone DCs. A and B are mean ± SEM of triplicates.

References

    1. Arbuckle MR, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–1533. - PubMed
    1. Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus. 2004;13:290–297. - PubMed
    1. Vlahakos DV, et al. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int. 1992;41:1690–1700. - PubMed
    1. Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: The role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol. 2007;25:419–441. - PubMed
    1. Martin DA, Elkon KB. Autoantibodies make a U-turn: The toll hypothesis for autoantibody specificity. J Exp Med. 2005;202:1465–1469. - PMC - PubMed

Publication types

MeSH terms